Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

3(42.9%)

Phase 4

2(28.6%)

Phase 2

1(14.3%)

N/A

1(14.3%)

7Total

Phase 3(3)

Phase 4(2)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06570057Not ApplicableRecruiting

Feasibility Trial in Urban Pakistan for Community Engagement in Preventing Type II Diabetes and Risk Factors

Role: collaborator

NCT01403350Phase 4Completed

Cluster Randomised Trial of Malaria RDTs Used by CHWs in Afghanistan

Role: collaborator

NCT00158561Phase 3Completed

Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria

Role: collaborator

NCT00158548Phase 3Completed

ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan

Role: collaborator

NCT00158587Phase 3Completed

Eight Week Primaquine Regimen for the Treatment of Vivax Malaria

Role: collaborator

NCT00935688Phase 4Completed

Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area

Role: collaborator

NCT00959517Phase 2Completed

Trial of Artesunate Combination Therapy in Pakistan

Role: collaborator

All 7 trials loaded